Trial Profile
A Phase 2a Study of SCY-635 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotype 1 Hepatitis C Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs SCY 635 (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors SCYNEXIS
- 13 Nov 2012 Results were presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), according to a SYNEXIS media release.
- 29 May 2012 Actual patient number is 11 according to ClinicalTrials.gov.
- 29 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.